Live data from 8 federal sources

Drug Intelligence for Benefits Decision‑Makers

Acquisition cost benchmarks, formulary coverage, Part D spending, and 340B risk analysis for 3,186 drugs. Powered by CMS, FDA, and HRSA data.

Top Drugs by Generic Competition

Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine and Amphetamine 22 mfrs · $0.2386/unit Pregabalin Lyrica 28 mfrs · $0.0458/unit Lamotrigine LAMICTAL 22 mfrs · $0.0292/unit Lisdexamfetamine Dimesylate Vyvanse 18 mfrs · $2.6475/unit Methylphenidate APTENSIO XR 28 mfrs · $0.0780/unit Levetiracetam Keppra 52 mfrs · $0.0304/unit Olanzapine ZYPREXA 25 mfrs · $0.0797/unit Quetiapine Quetiapine Fumarate 16 mfrs · $0.0289/unit Potassium Chloride KLOR-CON 36 mfrs · $0.0401/unit Metformin Glumetza 40 mfrs · $0.0140/unit Risperidone PERSERIS 25 mfrs · $0.0360/unit Topiramate Eprontia 23 mfrs · $0.0260/unit Venlafaxine Effexor 27 mfrs · $0.0689/unit Diltiazem CARTIA XT 24 mfrs · $0.0528/unit Tadalafil ADCIRCA 28 mfrs · $0.1044/unit Lenalidomide Revlimid 18 mfrs Aripiprazole ABILIFY 22 mfrs · $0.0977/unit Doxepin Doxepin 25 mfrs · $0.0783/unit Gabapentin GABARONE 28 mfrs · $0.0211/unit Estradiol Climara 21 mfrs · $0.0593/unit

Browse all 3,186 drugs →

Data Sources

RxFinder aggregates and cross-references data from eight government and regulatory sources, updated on rolling schedules from daily to quarterly. Every data point links to its authoritative source.

CMS NADAC FDA Orange Book openFDA NDC Directory CMS Part D Formulary CMS Part D Spending FDA Drug Shortages openFDA Enforcement HRSA 340B OPAIS